Page 182 - Read Online

Page 114 Ravegnini et al. Cancer Drug Resist 2019;2:107-15 I http://dx.doi.org/10.20517/cdr.2019.02

25. Akahoshi K, Oya M, Koga T, Shiratsuchi Y. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol
2018;24:2806-17.
26. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii21-6.
27. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. Efficacy and safety of imatinib mesylate in advanced
gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
28. Maleddu A, Pantaleo MA, Nannini M, Di Battista M, Saponara M, et al. Mechanisms of secondary resistance to tyrosine kinase
inhibitors in gastrointestinal stromal tumours (Review). Oncol Rep 2009;21:1359-66.
29. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, et al. Efficacy and safety of sunitinib in patients with advanced
gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
30. George S, Wang Q, Heinrich MC, Corless CL, Zhu M, et al. Efficacy and safety of regorafenib in patients with metastatic and/or
unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial. J Clin Oncol 2012;30:2401-7.
31. Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs
2009;23:377-89.
32. Vincenzi B, Nannini M, Grignani G, Fumagalli E, Gasperoni S, et al. Rechallenge in advanced GIST progressing to imatinib, sunitinib
and regorafenib: an Italian survey. J Clin Oncol 2017;35:11038.
33. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, et al. Drug resistance in cancer: an overview. Cancers (Basel) 2014;6:1769-92.
34. Lee JH, Kim Y, Choi JW, Kim YS. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in
gastrointestinal stromal tumors: a meta-analysis. J Gastrointestin Liver Dis 2013;22:413-8.
35. Künstlinger H, Huss S, Merkelbach-Bruse S, Binot E, Kleine MA, et al. Gastrointestinal stromal tumors with KIT exon 9 mutations:
update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Am J Surg Pathol
2013;37:1648-59.
36. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, et al. KIT mutations and dose selection for imatinib in patients
with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
37. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, et al. Correlation of kinase genotype and clinical outcome in the North
American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105
study by cancer and leukemia group B and Southwest oncology group. J Clin Oncol 2008;26:5360-7.
38. Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, et al. Ten-year progression-free and overall survival in patients with
unresectable or metastatic GI stromal tumors: long-term analysis of the European organisation for research and treatment of cancer,
Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels.
J Clin Oncol 2017;35:1713-20.
39. Kikuchi H, Miyazaki S, Setoguchi T, Hiramatsu Y, Ohta M, et al. Rapid relapse after resection of a sunitinib-resistant gastrointestinal
stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene. Anticancer Res 2012;32:4105-9.
40. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency,
spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-64.
41. Blay JY, Heinrich MC, Hohenberger P, Casali PG, Rutkowski P, et al. A randomized, double-blind, placebo-controlled, phase III study
of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: the CrenoGIST study. J Clin Oncol
2017;35:TPS11080.
42. Klug LR, Kent JD, Heinrich MC. Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.
Pharmacol Ther 2018;191:123-34.
43. Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, et al. Correlation of long-term results of imatinib in advanced
gastrointestinal stromal tumors with next-generation sequencing results. JAMA Oncol 2017;3:944-52.
44. Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J
Gastrointest Oncol 2017;8:466-73.
45. Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal
tumor. Cancer Chemother Pharmacol 2011;67:25-43.
46. Aparicio-Gallego G, Blanco M, Figueroa A, García-Campelo R, Valladares-Ayerbes M, et al. New insights into molecular mechanisms
of sunitinib-associated side effects. Mol Cancer Ther 2011;10:2215-23.
47. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, et al. Primary and secondary kinase genotypes correlate with the
biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352-9.
48. Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, et al. Long-term follow-up results of the multicenter phase II
trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor
therapy. Ann Oncol 2016;27:1794-9.
49. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, et al. KRAS and BRAF mutations predict primary resistance to imatinib in
gastrointestinal stromal tumors. Clin Cancer Res 2012;18:1769-76.
50. Franck C, Rosania R, Franke S, Haybaeck J, Canbay A, et al. The BRAF status may predict response to sorafenib in gastrointestinal
stromal tumors resistant to imatinib, sunitinib, and regorafenib: case series and review of the literature. Digestion 2019;99:179-84.
51. Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, et al. BRAF mutant gastrointestinal stromal tumor: first report of
regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget
2013;4:310-5.
52. Mussi C, Schildhaus HU, Gronchi A, Wardelmann E, Hohenberger P. Therapeutic consequences from molecular biology for